BioSpace News Archive

Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that members of its management team will present at the following industry conferences in Europe.

SEMINAL PRESENTATION OF FIRST ANALYTICAL VALIDATION DATA SCHEDULED FOR JUNE 30.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual R&D Day on July 12, 2022 at 12:00 pm ET.

Paraza Pharma is pleased to announce the appointment of Dr. Chudi Ndubaku as Chief Scientific Officer.

Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share.

RaySearch Laboratories AB (publ) will exhibit at PTCOG 60, to be held in Miami, Florida , USA, during June 27-July 1.

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.

BridgeBio Pharma, Inc. today announced positive Phase 1 data for BBP-711 in healthy volunteers, supporting the development of the investigational therapy for patients with primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formers.

Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Gregory S. Moss, Esq. , as chief corporate strategy and legal officer.